Charles River Laboratories International Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.89%.
Did CRL Beat Earnings? Q3 2025 Results
Charles River Laboratories posted a modest but meaningful beat in its third-quarter 2025 results, with non-GAAP EPS of $2.43 clearing the $2.34 consensus estimate by 3.86% and revenue of $1.00 billion edging past expectations by 1.42%, even as total sales slipped 0.5% year-over-year amid persistent softness in its core drug development services business. The primary bright spot was the Research Models and Services segment, which delivered 6.5% organic growth and margin expansion to 25.0%, helping offset continued weakness in the larger Discovery and Safety Assessment segment, where lower volumes compressed margins to 25.4% from 27.4% a year earlier. Adding a degree of relief to the quarter, regulators closed a long-running investigation into the company's non-human primate sourcing practices with no enforcement action recommended. Looking ahead, management narrowed its full-year non-GAAP EPS guidance to $10.10 to $10.30 and tightened the revenue outlook toward the upper end of prior ranges, though CEO James Foster cautioned that a sustained industry recovery remains a gradual and uncertain process.
- Higher revenue from large research model products drove RMS segment organic growth of 6.5%
- Lower sales volume for both discovery and regulated safety assessment services pressured DSA segment
- Lower revenue in CDMO and Biologics Testing businesses drove Manufacturing segment decline, partially offset by higher Microbial Solutions revenue
- Foreign currency translation provided a 1.3% benefit to reported revenue
- Cost savings from restructuring initiatives improved GAAP operating margin to 13.3% from 11.6%
- Loss of $0.33 per share from venture capital and strategic investments weighed on GAAP EPS
- Lower interest expense and reduced diluted share count from stock repurchases partially offset revenue declines on non-GAAP EPS
- Higher tax rate contributed to non-GAAP EPS decline
“Our solid third-quarter financial results demonstrate that the demand for our extensive portfolio of early-stage research and manufacturing products and services remains stable. We believe that positive signals are beginning to emerge which indicate that the industry may be on a path towards recovery; however, sustained improvement in our business will take time. There is still some uncertainty in the healthcare sector, so we are remaining cautious at this time.”
Charles River Laboratories CEO, on the earnings call
Forward Guidance & Outlook
The company narrowed its 2025 guidance to the middle and upper ends of prior ranges. Reported revenue growth is now expected at (1.5)% to (0.5)% (prior: (2.5)% to (0.5)%), with organic revenue decline of (2.5)% to (1.5)% (prior: (3.0)% to (1.0)%). The foreign exchange impact is approximately (1.0)%. Full-year non-GAAP EPS guidance was narrowed to $10.10–$10.30 (prior: $9.90–$10.30), and GAAP EPS to $4.15–$4.35 (prior: $4.25–$4.65). The guidance update reflects Q3 results that modestly exceeded the company's prior outlook. Management noted positive signals of industry recovery but cautioned that sustained improvement will take time amid ongoing healthcare sector uncertainty.
CRL YoY Financials
CRL Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.